Powder for reconstitution for enteral administration
Sponsors
Elgan Pharma Ltd.
Conditions
Intestinal Malabsorption
Phase 3
A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants
RecruitingCTIS2024-517101-87-00
Start: 2025-05-26Target: 295Updated: 2026-01-19
A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Safety of ELGN-2112 in Populations of Interest
RecruitingCTIS2024-517102-29-00
Start: 2025-11-19Target: 55Updated: 2025-11-20